Rapid Next-Generation Sequencing of Myeloid and Lymphoid Malignancy Samples

Over recent years there has been a continual expansion in the number of genetic alterations recommended for testing in the analysis of myeloid and lymphoid malignancy samples. Frequently, results are required in under 3-5 days. During this workshop, our speaker will discuss their use of the Ion Torrent™ Genexus™ System, a highly automated next-generation sequencing (NGS) system that can provide results within 24 hours. Targeted assays for myeloid and lymphoid samples enable rapid characterization of a broad range of DNA mutations and RNA fusion transcripts. Additionally, we’ll cover recent updates on highly sensitive NGS-based measurable residual disease (MRD) research.